 Recombinant granulocyte-macrophage colony-stimulating factor autologous bone marrow transplantation relapsed non-Hodgkin lymphoma blood bone marrow progenitor growth studies phase II Eastern Cooperative Oncology Group Trial Sixteen patients relapsed non-Hodgkin lymphoma underwent autologous bone marrow transplantation infusion recombinant human granulocyte-macrophage colony-stimulating factor rhGM-CSF Treatment involved-field radiotherapy mg/kg/d IV days total body irradiation cGy Autologous bone marrow IV hours first infusion IV rhGM-CSF micrograms/kg/d hours Infusions rhGM-CSF neutrophil count platelet count days marrow re-infusion Toxicities mild fever chills hypertension alopecia rash diarrhea stomatitis myalgias synovial knee effusions Neutrophil recovery median days range days marrow infusion comparable group historic controls counts median time days range days Median time self-sustaining platelet counts days range days comparable historic group bacteremia central venous catheter exit site infection Staphylococcus epidermidis local infection Giardia stool median range colony-forming unit granulocyte-macrophage CFU-GM progenitors kg Stem cell progenitors CFU-GM CFU-granulocyte erythroid monocyte megakaryocyte CFU-GEMM burst-forming unit-erythroid BFU-E bone marrow days marrow re-infusion proportion peripheral blood counts days transplant Neutrophils patients median decrease hours rhGM-CSF infusions data rhGM-CSF therapy enhances neutrophil recovery stem cells mature elements enhanced rate marrow stem cell early progenitor population sizes